Franklin Resources Inc. Raises Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Franklin Resources Inc. grew its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 8.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 332,405 shares of the biotechnology company's stock after purchasing an additional 26,668 shares during the quarter. Franklin Resources Inc. owned approximately 0.59% of Repligen worth $47,551,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Andra AP fonden bought a new stake in shares of Repligen in the second quarter worth about $25,000. UMB Bank n.a. grew its position in shares of Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock worth $33,000 after buying an additional 130 shares during the last quarter. Blue Trust Inc. increased its stake in shares of Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after buying an additional 127 shares during the period. Resources Management Corp CT ADV bought a new position in shares of Repligen during the third quarter valued at approximately $37,000. Finally, International Assets Investment Management LLC purchased a new stake in Repligen in the second quarter worth $33,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Stock Down 6.8 %

Shares of NASDAQ RGEN traded down $10.80 during trading on Wednesday, reaching $147.34. The company had a trading volume of 573,665 shares, compared to its average volume of 655,454. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13. The stock has a market cap of $8.26 billion, a PE ratio of -398.21, a P/E/G ratio of 4.64 and a beta of 0.96. The business's 50-day moving average is $143.61 and its 200 day moving average is $141.74. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm's revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.23 EPS. As a group, equities analysts forecast that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on RGEN. Wells Fargo & Company initiated coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 price objective for the company. Wolfe Research initiated coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a "peer perform" rating for the company. Royal Bank of Canada restated an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a report on Friday, November 22nd. Finally, Canaccord Genuity Group began coverage on Repligen in a research note on Tuesday. They issued a "hold" rating and a $165.00 target price for the company. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $185.20.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.